FDA CLEARANCE FOR THIO-101 APPROVED

$MAIA Biotechnology (MAIA.US)$ (RTTNews) - MAIA Biotechnology, Inc. (MAIA) announced the FDA has cleared Investigational New Drug application for THIO to be evaluated in the U.S. as part of THIO-101, the company's ongoing global phase 2 clinical study in patients with advanced Non-Small Cell Lung Cancer. THIO is being tested in sequential combination with Regeneron's anti PD-1 monoclonal antibody cemiplimab to evaluate anti-tumor activity and immune response in NSCLC patients.